Covid vaccine maker Novavax sees a pathway to survival – but it won’t be easyCash-strapped Covid vaccine Novavax still faces a nunber of challenges, chiefly competing with Pfizer and Moderna in the U.S. commercial market this fall.[Collection]

Cash-strapped Covid vaccine Novavax still faces a nunber of challenges, chiefly competing with Pfizer and Moderna in the U.S. commercial market this fall.https://www.cnbc.com/2023/06/14/why-novavax-path-to-survival-wont-be-easy-.html